Home/Filings/4/0001437749-20-023003
4//SEC Filing

Hanna John Walter JR 4

Accession 0001437749-20-023003

CIK 0001384101other

Filed

Nov 5, 7:00 PM ET

Accepted

Nov 6, 4:10 PM ET

Size

15.7 KB

Accession

0001437749-20-023003

Insider Transaction Report

Form 4
Period: 2020-11-05
Hanna John Walter JR
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2020-11-05$9.05/sh+3,125$28,28177,434 total
  • Exercise/Conversion

    Common Stock

    2020-11-05$5.98/sh+3,281$19,62080,715 total
  • Sale

    Common Stock

    2020-11-05$40.00/sh3,613$144,50677,102 total
  • Sale

    Common Stock

    2020-11-05$41.56/sh2,660$110,54874,442 total
  • Sale

    Common Stock

    2020-11-05$42.08/sh133$5,59774,309 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-11-053,1257,292 total
    Exercise: $9.05Exp: 2027-03-02Common Stock (3,125 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-11-053,28120,782 total
    Exercise: $5.98Exp: 2028-03-01Common Stock (3,281 underlying)
Footnotes (6)
  • [F1]The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020.
  • [F2]Represents weighted average sales price. Sale prices for the transactions range from $39.95 to $40.78. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  • [F3]Represents weighted average sales price. Sale prices for the transactions range from $41.01 to $42.01. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  • [F4]Represents weighted average sales price. Sale prices for the transactions range from $42.05 to $42.13. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  • [F5]The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
  • [F6]The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

Issuer

VERACYTE, INC.

CIK 0001384101

Entity typeother

Related Parties

1
  • filerCIK 0001781127

Filing Metadata

Form type
4
Filed
Nov 5, 7:00 PM ET
Accepted
Nov 6, 4:10 PM ET
Size
15.7 KB